Table 1.

Indications for RAI (adapted from NCCN 2012 guidelines).

Recommended
(i) All patients with gross extrathyroidal extension, primary tumor size > 4 cm, distant metastases	Papillary Follicular Hurthle
(ii) For select patients without gross residual disease when the combination of clinical factors predicts an intermediate to-high-risk for recurrence or disease-specific mortality (e.g., primary tumors ranging from 1–4 cm confined to the thyroid, high-risk histologies, vascular invasion, or cervical lymph node metastases)	Papillary
Not recommended
(i) Not routinely recommended for patients with either unifocal or multifocal papillary microcarcinomas (<1 cm) confined to the thyroid	Papillary
(ii) Not required: minimally invasive follicular thyroid carcinoma or Hurthle cell carcinoma confined to the thyroid when the primary tumor is small and demonstrates only invasion of the tumor capsule without vascular invasion	Follicular Hurthle